Mylan and the Department of Justice don’t seem to be on the same page these days.
On October 7, Mylan said agreed to pay $465 million to the Department of Justice and other government agencies over the way it classified the EpiPen in the Medicaid Drug Rebate Program. In the past few months, lawmakers have been accusing Mylan of overcharging Medicaid.
Mylan repeated the figure when it reported third-quarter earnings on Nov. 9. During a conference call with analysts that day, the company said it is still working with the DOJ to finalize that settlement.
